• Innovative Company SHIONOGI

What's New

  • Show All
2017/10/13
Shionogi Inc. and Purdue Pharma L.P. Announce U.S. Availability of Symproic® (naldemedine) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
2017/10/13
The dispute with the Boards of Appeal of the European Patent Office between Merck & Co., Inc. regarding HIV integrase inhibitor
2017/10/12
Shionogi Received “2017 Award for Excellence in Corporate Disclosure” From the Securities Analysts Association of Japan (SAAJ)
2017/10/06
SHIONOGI TO PRESENT S-033188 PHASE 3 CAPSTONE-1 STUDY RESULTS FOR TREATMENT OF INFLUENZA AT IDWEEK 2017
2017/10/05
SHIONOGI PRESENTS POSITIVE CLINICAL EFFICACY TRIAL RESULTS AND IN VITRO DATA ON CEFIDEROCOL, AT IDWEEK 2017
2017/09/28
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017
2017/09/25
Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures Rolling Submission of New Drug Application to FDA Initiated as Part of Fast Track Designation
2017/09/21
Shionogi to Announce Personnel Reassignment
2017/09/20
Shionogi Announces Positive Top-Line Results for INTUNIV®Evaluated in Phase 3 Clinical Trial in Adults with ADHD
2017/09/14
S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference
2017/09/08
Shionogi to Present New Data on S-033188,a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza,at the 6th European Scientific Working Group in Influenza Conference
2017/08/04
Audio webcasting: First Quarter of FY2017 Financial Results
2017/08/01
Audio webcasting: Top-Line Results for S-033188 Phase III Study in Otherwise Healthy Influenza Patients